Akeso Full Year 2023 Earnings: EPS Beats Expectations, Revenues Lag

Akeso (HKG:9926) Full Year 2023 Results

Key Financial Results

• Revenue: CN¥4.53b (up 440% from FY 2022).
• Net income: CN¥2.03b (up from CN¥1.17b loss in FY 2022).
• Profit margin: 45% (up from net loss in FY 2022). The move to profitability was driven by higher revenue.
• EPS: CN¥2.42 (up from CN¥1.42 loss in FY 2022).

9926 Products In Clinical Trials

• Phase I: 74.
• Phase III: 12.

9926 Post-Clinical Trial Products

• Pre-registration: 7.
• Approved (during full year): 1.

All figures shown in the chart above are for the trailing 12 month (TTM) period

Akeso EPS Beats Expectations, Revenues Fall Short

Revenue missed analyst estimates by 6.0%. Earnings per share (EPS) exceeded analyst estimates by 8.5%.

Looking ahead, revenue is forecast to grow 18% p.a. on average during the next 3 years, compared to a 26% growth forecast for the Biotechs industry in Hong Kong.

Performance of the Hong Kong Biotechs industry.

The company's shares are up 1.5% from a week ago.

Risk Analysis

What about risks? Every company has them, and we've spotted 1 warning sign for Akeso you should know about.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.